Stay Informed with Annovis News, Information, Activities and Other Updates

Corporate News

• May 4, 2022Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update
• April 28, 2022Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging
• April 11, 2022Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease
• March 23, 2022Annovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
• March 18, 2022Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022)
• March 8, 2022Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022
• March 3, 2022Annovis Bio to Present at the Cowen 42nd Annual Health Care Conference
• January 25, 2022Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease
• January 10, 2022Annovis Bio Enhances Leadership Team with Two Senior Appointments
• January 5, 2022Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401
• May 11, 2023Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update
• April 27, 2023Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans
• April 20, 2023ANNOVIS BIO PROVIDES UPDATED WEBCAST LINK AND DIAL-IN INFORMATION FOR TODAY'S R&D WEBCAST
• April 19, 2023ANNOVIS BIO ANNOUNCES UPDATE ON RECRUITMENT INTO ITS PHASE 2/3 ALZHEIMER'S STUDY AND UPCOMING R&D WEBCAST
• April 13, 2023ANNOVIS BIO TO HOLD LIVE WEBCAST TO REVIEW ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE CLINICAL PROGRAMS
• April 11, 2023ANNOVIS BIO RAISES AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $8.7 MILLION
• April 3, 2023Annovis Bio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
• March 22, 2023ANNOVIS BIO ANNOUNCES TWO PRESENTATIONS AT THE AD/PD™ 2023 INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASES
• February 8, 2023Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
• February 1, 2023Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses
• January 25, 2023ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON'S DISEASE
• January 6, 2023Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team
• November 8, 2022Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update
• October 20, 2022Annovis Bio to Present at the 2022 ThinkEquity Investor Conference
• October 11, 2022Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease
• October 6, 2022Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease
• September 29, 2022Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference
• September 13, 2022Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases
• September 8, 2022Annovis Bio's CEO Maria Maccecchini Issues Letter to Stockholders
• August 29, 2022Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer
• August 24, 2022Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease
• August 8, 2022Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update
• August 1, 2022Annovis Bio to Participate on Alzheimer's Association International Conference Panel
• July 14, 2022Annovis Bio to Present at the Alzheimer's Association International Conference
• July 7, 2022Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease
• June 9, 2022Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections
• December 14, 2021Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics
• November 15, 2021Annovis Bio Announces Transfer of Listing to the New York Stock Exchange
• November 12, 2021Annovis Bio Presented at the 14th Clinical Trials on Alzheimer’s Disease Conference
• November 9, 2021Annovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
• November 2, 2021Annovis Bio to Present at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
• October 5, 2021Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson’s Disease
• September 24, 2021Annovis Bio to Present at the Cantor Global Healthcare Conference
• September 10, 2021Annovis Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
• September 3, 2021Annovis Bio Interview to Air on Bloomberg U.S. on the RedChip Money Report®
• August 25, 2021Annovis Bio to Present at Biomarkers for Alzheimer’s Disease Summit 2021
• August 11, 2021Annovis Bio Completes Dosing of Parkinson’s Disease Patients with ANVS401 in Phase 2a Clinical Trial
• July 30, 2021Annovis Bio Pleased by Positive Interim Results from Ongoing Phase II Clinical Trials of ANVS401 (Posiphen) for the Treatment of Alzheimer's Disease and Parkinson's Disease
• July 28, 2021Annovis Bio Presents New Clinical and Biomarker Data at 2021 Alzheimer's Association International Conference
• July 23, 2021Annovis Bio to Present New Data at 2021 Alzheimer’s Association International Conference
• July 20, 2021Annovis Bio Reports Positive Safety Data from its Phase 2 Alzheimer’s Study
• July 2, 2021Annovis Bio to Present Data at Alzheimer's Association International Conference 2021 Highlighting Positive Clinical Outcomes from Its Two Phase 2a Trials
• July 1, 2021Annovis Bio CEO Wins 2021 PACT Enterprise Award for Life Sciences and Healthcare CEO
• June 24, 2021Annovis Bio CEO Selected as a Finalist in the 2021 PACT Enterprise Awards
• June 8, 2021Annovis Bio Expands Potential Application of ANVS401 to Infectious Diseases with New Preclinical Study
• June 3, 2021Annovis Bio to Present at Jefferies Virtual Healthcare Conference 2021
• June 1, 2021Annovis Bio’s ANVS401 Improves Speed and Accuracy in Alzheimer’s and in Parkinson’s Patients
• May 28, 2021Annovis Bio Engages Global Executive Search Leader Spencer Stuart to Expand its Board and Management Team
• May 27, 2021Annovis Bio, Inc. Announces Closing of $50 Million Public Offering
• May 23, 2021Annovis Bio, Inc. Announces Pricing of Public Offering
• May 21, 2021Annovis Bio, Inc. Announces Proposed Public Offering of Common Stock
• May 21, 2021Annovis Bio Announces Positive Phase 2 Data – ANVS401 Improves Cognition in Alzheimer’s Disease - Patients’ Cognition Improved 3.3 Points on ADAS-Cog11
• May 20, 2021Annovis Bio to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and hosted by M-Vest on May 26th, 2021
• May 20, 2021Annovis Bio Announces Positive Phase 2 Data: ANVS401 Significantly Lowers Inflammatory Markers in Parkinson's Patients
• May 18, 2021Annovis Bio Appoints Accomplished Neuroscientist Dr. Cheng Fang as VP of Research
• May 13, 2021Annovis Bio Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer’s Disease in Persons with Down Syndrome
• May 11, 2021Annovis Bio to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 13, 2021
• May 10, 2021Annovis Bio to Ring Closing Bell at the New York Stock Exchange
• May 6, 2021Annovis Bio Receives US Patent for Method of Treating Frontotemporal Dementia and Chronic Traumatic Encephalopathy
• April 29, 2021Annovis Bio to Study Potential of ANVS401 to Normalize Brain Development in Down Syndrome
• April 15, 2021Annovis Bio Appoints Reid McCarthy to Board and to Role of Audit Committee Chairman
• March 17, 2021Annovis Bio Presenting at M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference
• March 16, 2021Annovis Bio Announces Positive Phase 2 Data - Interim Data Shows ANVS401 Improves Speed and Coordination in Parkinson's Patients
• March 11, 2021Annovis Bio Signs GMP Manufacturing Agreement to Support Planned Late- Stage Studies
• March 11, 2021Annovis Bio, Inc. to present at the Q1 Virtual Investor Summit 
• March 10, 2021Annovis Bio Receives Japanese Patent for the Treatment of Acute Brain or Nerve Injury
• March 9, 2021Annovis Bio to Present at the H.C. Wainwright Global Life Sciences Conference
• February 16, 2021Annovis Bio to Present at the BIO CEO & Investor Digital Conference
• February 4, 2021Annovis Bio Receives European Patent for Method of Treating Acute Nerve and Brain Insults
• February 2, 2021Annovis Bio's Lead Candidate ANVS401 Improves Cognitive and Functional Outcomes in Stroke Mice Study
• January 5, 2021Annovis Bio to Present at H.C. Wainwright BioConnect 2021 Conference
• December 17, 2020Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
• December 15, 2020Annovis Bio Showcases its Unique Approach to Alzheimer’s at the New York Academy of Sciences
• December 7, 2020Annovis Bio to Present at Benzinga Global Small Cap Conference on December 8, 2020
• December 3, 2020Annovis Bio to Present at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference
• November 16, 2020Annovis Bio to Participate in A.G.P.'s Virtual Healthcare Symposium
• November 12, 2020Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer’s and Parkinson’s Diseases
• November 2, 2020Annovis Bio CEO to Present at Meridian Clinical Trials Summit
• October 29, 2020Annovis Bio Resumes Treatment of Patients in Ongoing Phase 2a Study in Alzheimer’s Disease after COVID-Related Delay
• October 22, 2020Annovis Bio CEO Receives 2020 Smart Business Dealmaker Award
• October 20, 2020Annovis Bio CEO Participates in Roundtable Discussion at the Financial Times’ Outstanding Directors Exchange and Panel Discussion at the Angel Venture Fair
• October 15, 2020Annovis Bio Provides Third Quarter 2020 and Year-to-Date Business Highlights
• October 12, 2020Annovis Bio to Present at the 2020 BIO Investor Forum
• September 29, 2020Annovis Bio Demonstrates Improved Axonal Transport in Nerve Cells and Brain of Down Syndrome Mice, an Animal Model of Alzheimer’s Disease
• September 3, 2020Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
• September 1, 2020Annovis Bio Begins Treatment of First Patients in its Phase 2a Alzheimer’s and Parkinson’s Trial
• August 20, 2020Annovis Bio Actively Recruiting Patients for its Phase 2a Trials in Alzheimer’s and Parkinson’s Diseases
• July 23, 2020Annovis Bio CEO Appears on Executive Leaders Radio Program
• July 20, 2020Annovis Bio CEO to Present the Company’s Novel Approach to Treating Parkinson’s Disease at University of Pennsylvania
• July 7, 2020Annovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s Patients
• June 16, 2020Annovis Bio Announces Positive Results from NIH Funded Chronic Toxicology Study
• June 9, 2020Annovis Bio to Present at the June 2020 Virtual Summer Investor Summit
• June 2, 2020Annovis Bio Issued European Patent for Method of Treating Alzheimer’s Disease with ANVS401
• June 1, 2020Annovis Bio 2020 Annual Meeting of Stockholders to Be Held on June 3, 2020
• May 27, 2020Annovis Bio Files Patent Application for Method of Inhibiting, Preventing, or Treating Neurological Injuries Due to Viral and Other Infections Including COVID-19
• May 1, 2020Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
• April 30, 2020Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68  Parkinson’s and Alzheimer’s Patients
• April 23, 2020Annovis Bio Publishes Results of Alzheimer’s and Parkinson’s Animal Studies
• April 13, 2020Annovis Bio to Hold Investor Webinar and Q&A Session with CEO on April 14
• February 27, 2020Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies
• February 20, 2020Annovis Issued Patent for Method of Treating Parkinson’s Disease and Other Lewy Body Diseases
• February 13, 2020Annovis Bio Announces Update on Phase II Clinical Trial for Alzheimer’s Disease
• January 31, 2020Annovis Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
• January 29, 2020Annovis Bio Announces Pricing of Initial Public Offering
• July 09, 2019Annovis Hires Jeff McGroarty as CFO
• June 24, 2019Annovis Name Change
• June 02, 2016QR News Release ADCS SILK Study
• May 06, 2016QR News Release Series A Financing
• January 05, 2015QR Pharma Chairman and Board
• October 09, 2013QR News Release US Army Grant Award
• March 06, 2012QR MJFF Funding
• November 10, 2011QR News Release Iris Newman Award
• December 02, 2010QR News Release IND for BNC Approved
• August 25, 2010Biz Life Science Awards
• July 14, 2010QR News Release Posiphen Clinical Data
• April 26, 2010CityBiz $2 million funding from BioAdvance and private investors Citibizlist
• February 24, 2010News Release Down Syndrome Patent
• June 08, 2009Philadelphia Inquirer QR Board
• November 20, 2008QR Newsrelease TPTX 2ndRelease ​